We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.17%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$512M
AUM Growth
+$116M
Cap. Flow
+$1.26M
Cap. Flow %
0.25%
Top 10 Hldgs %
44.62%
Holding
138
New
35
Increased
30
Reduced
28
Closed
26

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$31.8M
2
BIIB icon
Biogen
BIIB
+$21.2M
3
NVS icon
Novartis
NVS
+$19M
4
PFE icon
Pfizer
PFE
+$13M
5
CELG
Celgene Corp
CELG
+$8.38M

Top Sells

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$13.8M
2
CLCD
CoLucid Pharmaceuticals, Inc.
CLCD
+$13M
3
TEVA icon
Teva Pharmaceuticals
TEVA
+$11.9M
4
MRK icon
Merck
MRK
+$9.86M
5
AKAO
Achaogen Inc
AKAO
+$6.46M

Sector Composition

Rank Sector Weight
1 Healthcare 59.43%
2 Technology 4.38%
3 Communication Services 1.99%
4 Industrials 1.8%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
126
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-80,528
Closed -$383K
SIOX
127
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-12,500
Closed -$1.24M
GBT
128
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-125,000
Closed -$1.81M
ALXN
129
DELISTED
Alexion Pharmaceuticals
ALXN
– –
-113,000
Closed -$13.8M
MYOK
130
DELISTED
MyoKardia, Inc. Common Stock
MYOK
– –
-83,240
Closed -$1.08M
PTLA
131
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
– –
-100,000
Closed -$2.24M
HZNP
132
CALL
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
– –
-18,100
Closed -$293K
TSRO
133
DELISTED
TESARO, Inc.
TSRO
– –
-20,000
Closed -$2.69M
RXDX
134
DELISTED
Ignyta, Inc.
RXDX
– –
-22,065
Closed -$117K
CLCD
135
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
– –
-358,000
Closed -$13M
IMDZ
136
DELISTED
Immune Design Corp.
IMDZ
– –
-103,000
Closed -$567K
NDRM
137
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
– –
-175,951
Closed -$3.91M
2 3 4 5
6

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q1 2017 Portfolio in Review

As of Q1 2017, Sphera Funds Management held 138 positions worth $512M, up 29% from $395M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Sphera Funds Management's Q1 2017 filing shows 35 new, 30 increased, 28 reduced and 26 closed positions. Its largest new stake was Biogen: 75,000 shares worth $20.5M. The largest sale was Alexion Pharmaceuticals, an estimated $13.8M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 61% a quarter earlier, followed by Technology and Communication Services.

  • Sphera Funds Management's largest Q1 2017 buy was Biogen: 75,000 shares worth $20.5M.
  • Sphera Funds Management added most to Shire pic in Q1 2017, an estimated $31.8M increase.
  • Sphera Funds Management's biggest Q1 2017 reduction was Teva Pharmaceuticals, cutting an estimated $11.9M.
  • Sphera Funds Management fully exited Alexion Pharmaceuticals in Q1 2017, selling an estimated $13.8M.
  • Sphera Funds Management's ten largest holdings make up 45% of its $512M portfolio in Q1 2017.
  • Sphera Funds Management opened 35 new positions and closed 26 in Q1 2017.
  • Sphera Funds Management's portfolio value rose 29% quarter-over-quarter to $512M.

Based on Sphera Funds Management's 13F filing for Q1 2017, filed 11 May 2017.